Anti-lambda myeloma antrigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders
AssigneeHaemaLogix Pty Ltd
InventorRosanne Dunn
Life of this patent
Estimating the term…
Abstract
The present application is directed to anti-lambda myeloma antigen (LMA) binding proteins, wherein the binding protein is an antibody. Compositions comprising these antibodies and nucleic acids encoding these antibodies are also disclosed. These antibodies, compositions and nucleic acids may be used in the treatment of LMA expressing pathologies.
Claims26
An anti-lambda myeloma antigen (LMA) binding protein having an antigen binding domain, wherein the antigen binding domain preferentially binds LMA over free lambda light chain and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a complementarity determining region (CDR) 1 as shown in SEQ ID NO:
- 1, a CDR2 as shown in SEQ ID NO:
- 2 and a CDR3 as shown in SEQ ID NO:
- 3.
(canceled)
An anti-LMA binding protein having an antigen binding domain, wherein the antigen binding domain binds to LMA and comprises a VH and a VL, wherein:
- the VH comprises a CDR1 as shown in SEQ ID NO:
- 31, a CDR2 as shown in SEQ ID NO:
- 32 and a CDR3 as shown in SEQ ID NO:
- 33 and the VL comprises a CDR1 as shown in SEQ ID NO:
- 36 or SEQ ID NO:
- 41, a CDR2 as shown in SEQ ID NO:
- 37 or SEQ ID NO:
- 42 and a CDR3 as shown in SEQ ID NO:
- 38 or SEQ ID NO:
- 43;
- or,
- the VH comprises a CDR1 as shown in SEQ ID NO:
- 61, a CDR2 as shown in SEQ ID NO:
- 62 and a CDR3 as shown in SEQ ID NO:
- 63 and the VL comprises a CDR1 as shown in SEQ ID NO:
- 66 or SEQ ID NO:
- 71, a CDR2 as shown in SEQ ID NO:
- 67 or SEQ ID NO:
- 72 and a CDR3 as shown in SEQ ID NO:
- 68 or SEQ ID NO:
- 73.
An anti-LMA binding protein having an antigen binding domain, wherein the antigen binding domain binds to LMA and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
- the VH comprises an amino acid sequence shown in SEQ ID NO:
- 5 and the VL comprises an amino acid sequence shown in SEQ ID NO:
- 10 or SEQ ID NO:
- 15;
- the VH comprises an amino acid sequence shown in SEQ ID NO:
- 34 and the VL comprises an amino acid sequence shown in SEQ ID NO:
- 40 or SEQ ID NO:
- 45;
- the VH comprises an amino acid sequence shown in SEQ ID NO:
- 65 and the VL comprises an amino acid sequence shown in SEQ ID NO:
- 70 or SEQ ID NO:
- 75.
(canceled)
(canceled)
18-19. (canceled)
22-23. (canceled)
26-27. (canceled)
The method of claim 19, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, diabetes mellitus, and multiple sclerosis.
Dependencies are inferred from the claim text.